Liquidia Corp
NASDAQ:LQDA

Watchlist Manager
Liquidia Corp Logo
Liquidia Corp
NASDAQ:LQDA
Watchlist
Price: 10.65 USD 4.93% Market Closed
Market Cap: 894.6m USD
Have any thoughts about
Liquidia Corp?
Write Note

Gross Margin
Liquidia Corp

69.5%
Current
79%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
69.5%
=
Gross Profit
10.3m
/
Revenue
14.8m

Gross Margin Across Competitors

Country US
Market Cap 813.8m USD
Gross Margin
70%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 710.5B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 373.5B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 202.7B CHF
Gross Margin
73%
Country CH
Market Cap 183.3B CHF
Gross Margin
75%
Country UK
Market Cap 162.4B GBP
Gross Margin
82%
Country IE
Market Cap 146B USD
Gross Margin
68%
No Stocks Found

Liquidia Corp
Glance View

Market Cap
813.8m USD
Industry
Pharmaceuticals

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.

LQDA Intrinsic Value
5.84 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
69.5%
=
Gross Profit
10.3m
/
Revenue
14.8m
What is the Gross Margin of Liquidia Corp?

Based on Liquidia Corp's most recent financial statements, the company has Gross Margin of 69.5%.